tbuckley/cabot-search huggingface dataset:
Rethinking primary care’s gatekeeper role
Authors: Geva Greenfield, Kimberley Foley, Azeem Majeed
Journal: BMJ (2016)

Gatekeeping is the term used to describe the role of primary care physicians or general practitioners (GPs) in authorising access to specialty care, hospital care, and diagnostic tests. 1 Gatekeeping has crucial influences on service utilisation, health outcomes, healthcare costs, and patient satisfaction.In the UK access to NHS and private specialists is generally possible only after a referral from a GP.Gatekeeping was developed as a response to a shortage of specialists and a desire to control healthcare spending 2 and has been an accepted practice in the UK for over 100 years. 3The NHS is under considerable pressure to use its resources efficiently, and primary care has helped the NHS to achieve this goal through its gatekeeping function. 4Yet direct access could help reduce GP workload and facilitate greater patient choice.We look at the pros and cons of gatekeeping, describe gatekeeping policies in various countries, and highlight the need for more evidence to devise policy. Controversy around gatekeeping2][3][4][5][6] There are valid arguments for and against gatekeeping (table 1⇓). Patient choice and satisfactionEvidence on the effect of gatekeeping on quality of care and patient or provider satisfaction is inconsistent and limited. 10 11 Policies that limit direct access to specialists, and especially
PTX3 is a Novel Marker of Disease Progression in Alcoholic Hepatitis and Attenuates LPS-Induced Liver Injury and Inflammation
Authors: L. Perea, M. Coll, D. Rodrigo-Torres, D. Blaya, J. Altamirano, A. El Taghdouini, M. Llopis, I. Graupera, B. Aguilar, L. Van Grunsven, J. Caballería, P. Ginès, P. Sancho-Bru
Journal: Journal of Hepatology (2016)
Emricasan (IDN-6556) Orally for Three Months in Patients with Cirrhosis and Meld Scores 11–18 Improves Clinical Parameters of Cirrhosis in Patients with Baseline Meld Score ≥ 15
Authors: C. Frenette, G. Morelli, M. Shiffman, R.T. Frederick, R.A. Rubin, M. Fallon, M. Yamashita, A.P. Spada, J.L. Chan, D.T. Hagerty
Journal: Journal of Hepatology (2016)
Response assessment of aggressive and indolent non-Hodgkin's lymphoma by revised integrated international workshop criteria
Authors: Lieselot Brepoels, Sigrid Stroobants, Gregor Verhoef, Christiane De Wolf-Peeters, Karoline Spaepen, Peter Vandenberghe, José Thomas, Guy Bormans, Luc Mortelmans
Journal: Annals of Oncology (2006)
To Maintain Pediatric Competence, Walk With Our Patients and Families
Authors: David M. Keller, Nora Wells
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir with Ribavirin (AGATE-I)
Authors: T.I. Hassanein, T. Asselah, R.B. Qaqish, C. Hezode, J.-P. Mulkay, C. Moreno, M. ElKhashab, S. Alqahtani, Y. Yu, R. Redman, N. Mobashery
Journal: Journal of Hepatology (2016)
Proteomic Analysis of Liver Fibrotic Septa and Periportal Spaces in Primary Sclerosing Cholangitis, Primary Biliary Cholangitis and Alcoholic Liver Disease
Authors: G. Mazza, A. Telese, E. Schrumpf, J. Gilbertson, N. Rendell, B. Lombardi, J. Godovac-Zimmermann, G.W. Taylor, D. Thorburn, T.H. Karlsen, M. Pinzani
Journal: Journal of Hepatology (2016)
Immunopathology alters Th17 cell glucocorticoid sensitivity
Authors: J. Banuelos, Y. Cao, S. C. Shin, N. Z. Lu
Journal: Allergy (2016)

Th17 cells contribute to several inflammatory conditions and increasing evidence supports that Th17 cells are glucocorticoid resistant. However, Th17 cells in psoriasis and related diseases are glucocorticoid sensitive. We compare glucocorticoid sensitive and resistant immunological diseases and suggest that several aspects in Th17-related diseases alter glucocorticoid sensitivity of Th17 cells. We identify molecular pathways that are implicated in glucocorticoid sensitivity of Th17 cells in the literature, as this information is useful for developing approaches to overcome glucocorticoid-resistant immunopathology.
Inducible Expression of Leukemia-Associated Shp2 (Ptpn11) Affects Multiple Stages of Hematopoiesis and Causes a Fatal Myeloproliferative Disorder (MPD) in Mice
Authors: Gordon Chan, Demetrios Kalaitzidis, M. Golam Mohi, Wentian Yang, Jeffery Kutok, Benjamin Neel
Journal: Blood (2007)
Saturated Fatty Acid, Palmitate, Induced Liver Inflammation and Fibrosis in Vivo
Authors: Y. Ogawa, Y. Honda, T. Kessoku, W. Tomeno, S. Kato, K. Imajo, H. Mawatari, K. Hujita, S. Saito, A. Nakajima
Journal: Journal of Hepatology (2016)
Hyperphosphorylation of Antigenic Targets of Paraproteins In MGUS and Multiple Myeloma (MM) Is a Consistent Finding: Implications for the Pathogenesis of MGUS/MM
Authors: Sandra Grass, Klaus-Dieter Preuss, Aleksandra Wikowicz, Natalie Fadle, Evi Regitz, Stephan D. Thome, Henry T. Lynch, Michael Pfreundschuh
Journal: Blood (2010)
Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials
Authors: Nick Thatcher, Thomas J Lynch, Charles Butts, Rafael Rosell, Frances Shepherd, Jean-Louis Pujol, Johan Vansteenkiste, Michael Emig, Jutta Groos, Robert Pirker
Journal: Journal of Thoracic Oncology (2009)
High-Fat Diet and Glycation Impair Lipid and Glucose Metabolism Regulation in Rat Livers
Authors: C. Neves, J. Sereno, C. Simões, T. Rodrigues, J. Castelhano, J. Gonçalves, G. Bento, S. Gonçalves, R. Fonseca, M.R. Domingues, P. Matafome, M. Castelo-Branco, R. Seiça
Journal: Journal of Hepatology (2016)
First-line treatment patterns in advanced NSCLC in western Europe (EU), the United States, and Japan including a comparative analysis of younger versus elderly patients
Authors: J. F. Vansteenkiste, M. Koester, M. Lange, C. Eschbach
Journal: Journal of Clinical Oncology (2009)

8053 Background: The latest developments in advanced NSCLC are represented by targeted therapy (TT), treatment decisions based on tumor histology, and biomarker research. A patient (pt) case-based survey was conducted in three regions to study current pt characteristics and treatment patterns. Methods: 629 physicians treating stage III/IV NSCLC provided details on up to 10 of their pts. Results: Overall, 3455 EU pts, 895 US pts, and 600 Japanese pts were monitored. This analysis focuses on the 89% of pts with stage IIIb/IV NSCLC. In each region, median age, gender, and occurrence of malignant pleural effusion were comparable but tumor histology differed slightly. Comparative analyses revealed that monotherapy (MT) with either chemotherapy (CT) or TT agents is used significantly more in elderly pts (≥70 yrs) while combination therapy (CT/TT doublets or triplets) is more frequent in younger pts. This is consistent across all regions and histologies (squamous vs non-squamous). In the EU, 48.3% of elderly and 13.6% of younger pts received MT (39.9% vs 15.1% for US pts, 32.0% vs 9.4% for Japanese pts). CT/TT doublets were used predominantly in younger vs elderly pts (72.3% vs 48.1% in the EU, 47.3% vs 36.9% in the US, and 81.7% vs 65.5% in Japan). Triplets were also more widely used in younger vs elderly pts (14.3% vs 3.6% in the EU, 36.3% vs 22.6% in the US, and 6.5% vs 1.8% in Japan). For both age groups, the leading MTs are erlotinib in the EU and US, and gefitinib in Japan but use is higher in elderly pts. Preferred doublets in the EU are platinum+gemcitabine (28.8%), platinum+vinorelbine (13.6%) and platinum+taxanes (13.5%). Platinum+taxanes is predominant in the US and Japan (27.7% and 55.4%, respectively). The triplets, bevacizumab+platinum+taxanes (27.0%) and bevacizumab+platinum+other (3.5%), are also common in the US while these treatments only represent 5.1% and 3.9%, respectively, in the EU. Conclusions: Important regional differences in 1 st -line advanced NSCLC treatment exist with triplets being more common in the US only. MT is more frequent in elderly pts and combination therapy is more common in younger pts. This latter finding is consistent across all regions and histological subsets. [Table: see text]
Complete Response under Sorafenib Treatment for Hepatocellular Carcinoma is Associated to Development of Dermatology Adverse Events
Authors: Á. Díaz-González, J. Rimola, R. María, A. Darnell, M. Varela, F. Pons, M. Hernández-Guerra, M. Delgado, J.F. Castroagudín, A. Matilla, B. Sangro, C.R. de Lope, S. Margarita, C. González, C. Huertas, B. Minguez, C. Ayuso, J. Bruix
Journal: Journal of Hepatology (2016)
Risk Statification of Follicular Lymphomas Using Two Independent Prognostic Factors: Lymphoma Cell Size Assessment by Flow Cytometry and FDG PET Based Metabolic Activity
Authors: Mohammad Muhsin Chisti, Govinda R. Brahmanday, Alaa A Muslimani, Siddhartha Yadav, Paul Rigo, Ching-yee Oliver Wong, Ishmael Jaiyesimi, James Huang
Journal: Blood (2012)
Efficacy of Yttrium-90 Zevalin Outside of Clinical Trials: Preliminary Results of a Retrospective Bi-Center Study
Authors: Francesco Cicone, Francesco Scopinaro, Sebastien Baechler, Nicolas Ketterer, Franz Buchegger, M. Christina Cox, Gilles Allenbach, Anna Tofani, Angelika Bischof Delaloye
Journal: Blood (2008)
Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).
Authors: Rosario Garcia Campelo, Enriqueta Felip, Bartomeu Massuti, Margarita Majem, Enric Carcereny Costa, Ramon Palmero, Miguel Angel Molina-Vila, Pablo Martinez, Juan Luis Marti-Ciriquian, Guillermo Alonso-Jaudenes Curbera, Cinta Pallares, Felipe Cardenal, Maria Carmen Gonzalez-Arenas, Clara Mayo-de las Casas, Maria Sanchez-Ronco, Rafael Rosell
Journal: Journal of Clinical Oncology (2014)

8079 Background: Progression-free survival (PFS) and response rate (RR) to EGFR tyrosine kinase inhibitors (TKIs) vary in P with NSCLC driven by EGFR mutations, suggesting that other genetic alterations may influence oncogene addiction. High BRCA1 mRNA expression negatively influenced PFS among EGFR mutant P treated with erlotinib. We hypothesized that since olaparib can attenuate and/or prevent BRCA1 expression, the addition of olaparib to gefitinib could improve PFS in these P. Methods: This is a Phase IB dose escalation study (standard 3+3 design) to identify the maximum tolerated dose (MTD), dose limiting toxicity (DLT), pharmacokinetics (PK), and clinical activity of orally administered olaparib in combination with gefitinib in EGFR mutant advanced NSCLC. P were treated with gefitinib 250mg once daily plus olaparib at escalating doses ranging from 100mg BID to 250mg TDS during a 28-day cycle. Results: Twenty-two P were included across four dose levels of olaparib: 100mg BID (3), 200mg BID (6), 200mg TDS (6) and 250mg TDS (7). Most common toxicities were G1-2, including anemia, leucopenia, nausea, diarrhea, asthenia, rash and anorexia; G3 drug-related events included lymphopenia (1) and anemia (3). No DLT at dose levels 1 and 2; 1 DLT at dose level 3, and 2 at dose level 4 (G3 anemia and repeated blood transfusion within 4-6 weeks). Thirteen P harbored concomitant sensitizing mutation (exon 19 del or L858R mut) plus T790M (5 previously treated, and 7 untreated P). Twenty-one P were evaluated for response: for those not previously treated, complete responses (CR) were observed in 1 r75966P (7.1%) partial responses (PR) in 9 P (69.2%), stable disease (SD) in 3 P (23%) and no progressive disease (PD) (0%). In P previously with TKI, 3 (37.5%) had PR, 3 (37.5%) SD, and 2 (25.5%) PD. Durable PR and SD were observed in both EGFR TKI-naïve and previously treated P. Conclusions: This phase IB trial of gefitinib plus olaparib confirms tolerability of the combination and the activity seen warrants further exploration in treatment-naïve patients. MTD of olaparib was 200mg TDS. Clinical trial information: NCT01513174.
Development of a Prognostic Scoring System for Patients Undergoing Liver Resection for Hepatocellular Carcinoma
Authors: C. Sposito, S. Di Sandro, F. Brunero, G. Concone, C. Battiston, V. Buscemi, M. Bongini, L. De Carlis, V. Mazzaferro
Journal: Journal of Hepatology (2016)
P1262 : An accurate score for the prediction of sustained viral response under protease inhibitor-based triple therapy in cirrhotic patients: The cupic algorithm – the ANRS CO20 CUPIC study
Authors: J. Boursier, P. Veillon, J. Vergniol, V. Moal, C. Dufour, J.-P. Bronowicki, D. Larrey, C. Hézode, F. Carrat, F. Zoulim, H. Fontaine, T. Poynard, V. Canva, P. Cacoub, P. Attali, M. Bourlière, L. Alric, J.-P. Zarski, S. Allam, P. Calès, V. De Lédinghen
Journal: Journal of Hepatology (2015)
Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies.
Authors: Stephane Depil, Olivier Morales, Bernard Maillere, Nadira Delhem, Violaine Francois, Bertrand Georges, Franck Morschhauser, Claude Auriault, Veronique Pancre
Journal: Blood (2005)
Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors
Authors: Candace D Middlebrooks, A Rouf Banday, Konichi Matsuda, Krizia-Ivana Udquim, Olusegun O Onabajo, Ashley Paquin, Jonine D Figueroa, Bin Zhu, Stella Koutros, Michiaki Kubo, Taro Shuin, Neal D Freedman, Manolis Kogevinas, Nuria Malats, Stephen J Chanock, Montserrat Garcia-Closas, Debra T Silverman, Nathaniel Rothman, Ludmila Prokunina-Olsson
Journal: Nature Genetics (2016)
National survey of colistin resistance among carbapenemase-producing Enterobacteriaceae and outbreak caused by colistin-resistant OXA-48-producing Klebsiella pneumoniae, France, 2014
Authors: Aurélie Jayol, Laurent Poirel, Laurent Dortet, Patrice Nordmann
Journal: Eurosurveillance (2016)

From January 2014 to December 2014, 972 consecutive non-replicate carbapenemase-producing Enterobacteriaceae isolates from colonised or infected patients were collected at the Associated French National Reference Centre as part of the French national survey on antimicrobial resistance. It included 577 Klebsiella spp. (59%), 236 Escherichia coli (24%), 108 Enterobacter spp. (11%), 50 Citrobacter spp. (5%), and a single Salmonella spp. isolate (0.1%). Of 561 K. pneumoniae isolates, 35 were found to be resistant to colistin (6.2%). PFGE analysis revealed a clonal outbreak involving 15 K. pneumoniae isolates belonging to sequence type ST11, recovered in a single hospital in the Picardie region in northern France. Those clonally related isolates showed variable levels of resistance to colistin, ranging from 4 to 64 mg/L. They harboured the bla OXA-48 carbapenemase gene and the bla CTX-M-15 extended-spectrum beta-lactamase gene. Among the 91 Enterobacter cloacae isolates, seven were resistant to colistin and produced different types of carbapenemases. Surprisingly, none of the E. coli and Citrobacter spp. isolates showed resistance to colistin. This national survey including carbapenemase-producing isolates recovered in 2014 reported a high rate of colistin resistance in K. pneumoniae and E. cloacae (6.2% and 7.7%, respectively) in France.
Mutational analysis of 29 patients with autosomal-recessive woolly hair and hypotrichosis: <i>LIPH</i> mutations are extremely predominant in autosomal-recessive woolly hair and hypotrichosis in Japan
Authors: T. Takeichi, K. Tanahashi, T. Taki, M. Kono, K. Sugiura, M. Akiyama
Journal: British Journal of Dermatology (2016)

Autosomal recessive woolly hair and hypotrichosis (ARWH) is a rare form of congenital alopecia characterized by sparse hair on the scalp, and it sometimes expands to all the body hair. ARWH is known to be caused by mutations in LIPH or LPAR6.1,2 Recently, Zernov et al. reported that the KRT25 gene causes autosomal-recessive hypotrichosis with woolly hair.3

LIPH encodes a membrane-bound member of the mammalian triglyceride lipase family, lipase H.1 LPAR6 encoded by LPAR6 and LIPH are both involved in the same pathway of regulation of hair differentiation and growth.1,2 To date, 24 pathogenic mutations in LIPH have been reported in ARWH (w w w . hgmd. cf .ac .uk, as of HGMD professional, 2016.1). They comprise 9 missense/nonsense, 2 splice-site, 5 small-deletion, 2 small-insertion, 3 small-indel, 2 gross-deletion and 1 gross-insertion mutations. Of these, the 2 mutations c.736T>A and c.742C>A in LIPH have been reported as extremely prevalent causative mutations for ARWH in the Japanese population. We confirmed the high frequencies of the 2 founder mutations, especially of c.736T>A, in 819 Japanese controls.4 The LIPH mutations c.736T>A (p.Cys246Ser) and c.742C>A (p.His248Asn) were proven to be dysfunctional by in vitro studies.5 Precisely how often these two founder mutations in LIPH are seen in Japanese ARWH patients remains uncertain.

This article is protected by copyright. All rights reserved.
Efficacy and Safety of IFN Free, Direct-Acting Antiviral-Based Treatment Regimens in Patients with Advanced Liver Disease: Community Treatment of a Real World Population in France
Authors: D. Ouzan, G. Penaranda, P. Delasalle, C. Renou, B. Hanslik, M. Antoni, P. Toulemonde, T. Fontanges, S. Bresson-Hadni, P. Halfon, N. Boyer, J. Liautard, S. Baesjou, C. Bonny, P. Cerdan, M. Bourlière
Journal: Journal of Hepatology (2016)
Backtracking Subclonal Mutations Of TP53 In Myelodysplasia (MDS) With Del(5q) With Next-Generation Sequencing (NGS)
Authors: Laurence Lodé, Audrey Ménard, Marion Loirat, Maxime Halliez, Steven Richebourg, Pascaline Talmant, Catherine Godon, Olivier Theisen, Yannick Le Bris, Cécile Girard, Nicolas Blin, Odile Luycx, Sophie Sadot-Lebouvier, Nadine Morineau, Pascal Godmer, François Subiger, Bruno Villemagne, Marion Eveillard, Soraya Wuillème, Alexander Kohlmann, Philippe Moreau, Jacques Delaunay, Marie C Bene
Journal: Blood (2013)
Impact of Bivalirudin Monotherapy on 30-day Outcomes in Patients with Acute Coronary Syndromes and Complex Coronary Stenoses Undergoing Percutaneous Coronary Intervention
Authors: Kenji Goto, Alexandra J Lansky, Ecaterina Cristea, Martin Fahy, Frederick Feit, Magnus E Ohman, Harvey D White, Karen P Alexander, Michel E Bertrand, Walter Desmet, Martial Hamon, Roxana Mehran, Gregg W Stone
Journal: Journal of the American College of Cardiology (2009)
EFFECT OF CALCITONIN-GENE-RELATED PEPTIDE IN PATIENTS WITH DELAYED POSTOPERATIVE CEREBRAL-ISCHEMIA AFTER ANEURYSMAL SUBARACHNOID HEMORRHAGE
Authors: Ic Bailey, Ja Lyttle, B Matthew, G Braadvedt, Rj Nelson, G Stranjalis, Jp Castel, Jm Orgogozo, Am Aziz, Tf Buckley, Rg Galvin, A Keshtgar, Jc Marks, J Hutchison, Sa Olaoire, J Singh, Jd Miller, Gd Murray, Gm Teasdale, D Grosset, P Foy, Prd Humphrey, K Morris, Mdm Shaw, Ba Bell, Fg Johnston, M. R. Stapleton, Was Taylor, Adam Bartlett, D Dorrance, Rw Gullan, Ija Robertson, L Calandre, Rd Lobato, M Barnes, U Choksey, Ja Cozens, J Mcmahon, Ad Mendelow, Dt Hope, D Jefferson, B White, Y Kereval, D Mohan, Ps Dias, S Howell, J Jakubowski, B Martin, J Martin, Jd Pickard, J Stanley, J Lagarrigue, V Larrue, Op Dahl, R Juul
Journal: The Lancet (1992)
US to impose tougher rules on reporting clinical trial data
Authors: Michael McCarthy
Journal: BMJ (2016)

Researchers conducting clinical trials in the US will be required to provide more information about their studies when they initially register their trials and more detailed results upon their trials’ completion under two sets of new rules.

The rules were released on 16 September by the US Department of Health and Human Services1 and the National Institutes of Health (NIH).2

Francis Collins, director of NIH, said that the new rules will help maximize the value of clinical trials and fulfill researchers’ commitment to trial participants. “Access to more information about clinical trials is good for …
A Novel Tissue-Restricted Minor Histocompatibility Antigen Resulting from Differential Expression Due to a Deletion/Insertion Polymorphism in the P2X5 Purinergic Receptor Gene.
Authors: Harry Dolstra, Bjorn de Rijke, Agnes van Horssen, Frans Maas, Britt Otterud, Elly van de Wiel-van Kemenade, Theo De Witte
Journal: Blood (2004)
Liver Cirrhosis is Characterized by an Acquired Lysosomal Acid Lipase Deficiency Independent from the Etiology of Liver Disease
Authors: U. Vespasiani-Gentilucci, P. Gallo, A. Porcari, F. Vorini, L. Piccioni, G. Galati, A. De Vincentis, C. Dell’Unto, F. Piemonte, G. Tozzi, E. Riva, A. Picardi
Journal: Journal of Hepatology (2016)
Use of not authorised stem-cell based products: The Committe for Advanced Therapies (CAT) perspective
Authors: C Schneider, P Salmikangas, B Jilma, B Flamion, LR Todorova, A Paphitou, I Haunerova, S Thirstrup, T Maimets, JH Trouvin, E Flory, A Tsiftsoglou, B Sarkadi, K Gudmundsson, M O'Donovan, G Migliaccio, J Ancans, R Maciulaitis, JL Robert, A Samuel, H Ovelgönne, M Hystad, AM Fal, B Silva Lima, AS Moraru, P Turcani, B Zorec, S Ruiz, L Akerblom, G Narayanan, A Kent, F Bignami, G Dickson, D NIederwieser, Maf Santos, M Clausen, J Gulbinovic, M Menezes-Ferreira, M Timon, IG Reischl, C Beuneu, R Georgiev, M Vassiliou, A Pychova, T Methuen, S Lucas, Kokkas, Z Buzas, N MacAleenan, MC Galli, A Line, G Berchem, M Fraczek, N Vilceanu, M Hrubisko, P Marinko, WS Cheng, GA Crosbie, N Meade, M Lipucci di Paola, Thierry Vandendriessche, P Ljungman, L D'Apote, O Oliver-Diaz, I Büttel, P Celis
Journal: The Lancet (2010)
Misleading meta-analysis
Authors: R Persaud
Journal: BMJ (1996)

1991 that half of 999 calls resulted in the patient being discharged with no follow Up.3Campaigns to educate the public about making more appropriate use of the service may help to reduce the burden on emergency ambulances, but with attitudes such as "It's free-why shouldn't I call an ambulance?"then perhaps the only way forward is to implement a tiered system.
Differential Expression of Genes Associated with Toll-Like Receptor-4 (TLR4) Signal Transduction Pathway in Lipopolysaccharide (LPS)-Activated Cord Blood (CB) vs. Adult Peripheral Blood (APB) Monocyte (Mo)-Derived Dendritic Cells (DC).
Authors: Hong Jiang, Mary Brigid Bradley, Carmella van de Ven, Prakash Satwani, Laxmi Baxi, Mitchell S. Cairo
Journal: Blood (2004)
Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt
Authors: R. Anty, A. Coilly, C. Fougerou, V. De Ledinghen, P. Houssel-Debry, C. Duvoux, V. Di Martino, S. Radenne, N. Kamar, L. D’Alteroche, V. Canva, P. Lebray, C. Moreno, J. Dumortier, C. Silvain, C. Besch, D. Botta-Fridlund, V. Leroy, F. Durand, A. Tran, H. Montialoux, F. Habersetzer, G. Favre, E. Rossignol, A. Rohel, A. Renault, S. Dharancy, H. Danjou, J.-C. Duclos-Vallee, G.-P. Pageaux
Journal: Journal of Hepatology (2016)